Shield Therapeutics Share Price (STX)

0.00 0.00 (0.00%) delayed: 4:08AM GMT
Bid price 53.00 Open price 0.00
Ask price 54.00 Prev close 53.50
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live Shield Therapeutics share prices, Shield Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Shield Therapeutics Level 2 Data, indepth research tools and investor commentary for Shield Therapeutics (STX) and other London Stock Exchange equities.

Shield Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Shield Therapeutics share price charts

Shield Therapeutics Share Price Information

Name Shield Therapeutics Epic STX
Sector Pharmaceuticals & Biotechnology ISIN GB00BYV81293
Activites Shield Therapeutics plc is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. Index n/a

Shield Therapeutics Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) -21.21
Market Capitalisation (£m) 56.47 Gross Gearing (%) 8.37
Shares in issue (m) 116.43 Debt Ratio 0.00
P/E Ratio -2.85 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.09
Dividend Yield (%) 0.00 Price to book value 1.37
Dividend cover (x) 0.00 ROCE (%) -50.93
Earning per share (p) -17.00 EPS Growth (%) -13.33
52 week high / low 63.00 / 15.10 DPS Growth (%) n/a

Shield Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
24/09/2018 BUY Carl Sterritt CEO 88,235
05/10/2017 BUY Carl Sterritt CEO 8,814

More Shield Therapeutics Director Deals >>

Shield Therapeutics Company News

08:00 19/02/2019

Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics Plc

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 116p (from 80p). Story provided by Broker Forecasts data provided by

08:07 29/01/2019

Shield Therapeutics reports promising results from iron-deficiency treatment study

Shield Therapeutics reported positive results from a further study of a treatment for iron deficiency in adults with inflammatory bowel disease. The open-label extension phase of the study of Feraccru was a pivotal phase III randomized, placebo-controlled, double-blind trial in chronic kidney...

07:00 29/01/2019

Positive results of AEGIS-CKD study

RNS Number : 3356O Shield Therapeutics PLC 29 January 2019   Shield Therapeutics plc ("Shield" or the "Group")   Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru ®   ·     Haemoglobin levels increased and...

More Shield Therapeutics Company News >>

Register now for FREE Shield Therapeutics company news

Shield Therapeutics Share Price Discussions

more than 1 year ago

Seagate Technology (STX)

traded on Nasdaq - anyone holding? PE of 4 and company on a buy back mission

Register now for FREE Shield Therapeutics share price discussions